Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Chesler

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
Neuro-Oncology|October 8, 2024
MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastomaMagretta Adiamah, Bethany Poole, Janet C Lindsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM Emmy M Dolman, Evon Poon, Marli E Ebus, et al.
Cancer Letters|February 1, 2025
ATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastomaFederica Lorenzi, Sina Jostes, Qiong Gao, et al.
Ebiomedicine|August 27, 2020
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSally L George, Federica Lorenzi, David King, et al.
Nature Cancer|March 26, 2021
Combined inhibition of Aurora-A and ATR kinase results in regression of <i>MYCN</i>-amplified neuroblastomaIsabelle Roeschert, Evon Poon, Anton G Henssen, et al.
Brain Pathology (Zurich, Switzerland)|May 9, 2017
Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngiomaJessica K R Boult, John R Apps, Annett Hölsken, et al.
Acta Neuropathologica Communications|November 21, 2013
Identification of a neuronal transcription factor network involved in medulloblastoma developmentMaria Lastowska, Hani Al-Afghani, Haya H Al-Balool, et al.
Cancer Research|June 30, 2020
Noninvasive MRI Native T<sub>1</sub> Mapping Detects Response to <i>MYCN</i>-targeted Therapies in the Th-<i>MYCN</i> Model of NeuroblastomaKonstantinos Zormpas-Petridis, Evon Poon, Matthew Clarke, et al.
Cell Reports|August 24, 2025
MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibitionGregor A Lueg, James Zhang, Monica Faronato, et al.
The Lancet. Oncology|July 6, 2017
From class waivers to precision medicine in paediatric oncologyAndrew D J Pearson, Stefan M Pfister, Andre Baruchel, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
Neuro-Oncology|October 8, 2024
MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastomaMagretta Adiamah, Bethany Poole, Janet C Lindsey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM Emmy M Dolman, Evon Poon, Marli E Ebus, et al.
Cancer Letters|February 1, 2025
ATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastomaFederica Lorenzi, Sina Jostes, Qiong Gao, et al.
Ebiomedicine|August 27, 2020
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSally L George, Federica Lorenzi, David King, et al.
Nature Cancer|March 26, 2021
Combined inhibition of Aurora-A and ATR kinase results in regression of <i>MYCN</i>-amplified neuroblastomaIsabelle Roeschert, Evon Poon, Anton G Henssen, et al.
Brain Pathology (Zurich, Switzerland)|May 9, 2017
Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngiomaJessica K R Boult, John R Apps, Annett Hölsken, et al.
Acta Neuropathologica Communications|November 21, 2013
Identification of a neuronal transcription factor network involved in medulloblastoma developmentMaria Lastowska, Hani Al-Afghani, Haya H Al-Balool, et al.
Cancer Research|June 30, 2020
Noninvasive MRI Native T<sub>1</sub> Mapping Detects Response to <i>MYCN</i>-targeted Therapies in the Th-<i>MYCN</i> Model of NeuroblastomaKonstantinos Zormpas-Petridis, Evon Poon, Matthew Clarke, et al.
Cell Reports|August 24, 2025
MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibitionGregor A Lueg, James Zhang, Monica Faronato, et al.
The Lancet. Oncology|July 6, 2017
From class waivers to precision medicine in paediatric oncologyAndrew D J Pearson, Stefan M Pfister, Andre Baruchel, et al.
Pageof 12